Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.250
+0.280 (9.43%)
Nov 22, 2024, 4:00 PM EST - Market closed

Fulcrum Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2017
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2017
Revenue
80.872.816.3419.168.82-
Upgrade
Revenue Growth (YoY)
2987.86%-55.77%-66.90%117.19%--
Upgrade
Cost of Revenue
70.6771.876.7869.759.0471.07
Upgrade
Gross Profit
10.2-69-70.44-50.54-50.22-71.07
Upgrade
Selling, General & Admin
38.641.6741.6930.5221.3913.15
Upgrade
Operating Expenses
38.641.6741.6930.5221.3913.15
Upgrade
Operating Income
-28.4-110.66-112.13-81.05-71.61-84.22
Upgrade
Interest & Investment Income
12.5513.332.690.210.791.54
Upgrade
EBT Excluding Unusual Items
-15.85-97.34-109.44-80.85-70.82-82.68
Upgrade
Merger & Restructuring Charges
-2.06--0.43---
Upgrade
Pretax Income
-17.91-97.34-109.87-80.85-70.82-82.68
Upgrade
Net Income
-17.91-97.34-109.87-80.85-70.82-82.68
Upgrade
Preferred Dividends & Other Adjustments
-----7.13
Upgrade
Net Income to Common
-17.91-97.34-109.87-80.85-70.82-89.81
Upgrade
Shares Outstanding (Basic)
626145352511
Upgrade
Shares Outstanding (Diluted)
626145352511
Upgrade
Shares Change (YoY)
5.50%36.27%27.23%39.47%129.53%778.76%
Upgrade
EPS (Basic)
-0.29-1.59-2.44-2.29-2.79-8.13
Upgrade
EPS (Diluted)
-0.29-1.59-2.44-2.29-2.79-8.13
Upgrade
Free Cash Flow
-8.74-91.47-99.01-80.19-55-40.43
Upgrade
Free Cash Flow Per Share
-0.14-1.49-2.20-2.27-2.17-3.66
Upgrade
Gross Margin
12.61%---263.73%--
Upgrade
Operating Margin
-35.11%-3945.24%-1768.12%-422.97%-811.64%-
Upgrade
Profit Margin
-22.15%-3470.05%-1732.43%-421.89%-802.66%-
Upgrade
Free Cash Flow Margin
-10.81%-3261.07%-1561.23%-418.47%-623.34%-
Upgrade
EBITDA
-26.67-108.49-109.72-78.54-69.23-82.16
Upgrade
D&A For EBITDA
1.732.172.412.522.382.05
Upgrade
EBIT
-28.4-110.66-112.13-81.05-71.61-84.22
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.